Salarius Pharmaceuticals (SLRX) Competitors $0.90 +0.02 (+2.45%) Closing price 04:00 PM EasternExtended Trading$0.88 -0.01 (-1.54%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. KPRX, BTAI, BCLI, SNSE, CYCN, DWTX, TLPH, TRAW, KZIA, and LSBShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Kiora Pharmaceuticals (KPRX), BioXcel Therapeutics (BTAI), Brainstorm Cell Therapeutics (BCLI), Sensei Biotherapeutics (SNSE), Cyclerion Therapeutics (CYCN), Dogwood Therapeutics (DWTX), Talphera (TLPH), Traws Pharma (TRAW), Novogen (KZIA), and LakeShore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Its Competitors Kiora Pharmaceuticals BioXcel Therapeutics Brainstorm Cell Therapeutics Sensei Biotherapeutics Cyclerion Therapeutics Dogwood Therapeutics Talphera Traws Pharma Novogen LakeShore Biopharma Kiora Pharmaceuticals (NASDAQ:KPRX) and Salarius Pharmaceuticals (NASDAQ:SLRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Which has more volatility and risk, KPRX or SLRX? Kiora Pharmaceuticals has a beta of -0.66, suggesting that its stock price is 166% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Does the media prefer KPRX or SLRX? In the previous week, Kiora Pharmaceuticals' average media sentiment score of 1.89 beat Salarius Pharmaceuticals' score of 1.87 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Kiora Pharmaceuticals Very Positive Salarius Pharmaceuticals Very Positive Do institutionals & insiders have more ownership in KPRX or SLRX? 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of Salarius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is KPRX or SLRX more profitable? Kiora Pharmaceuticals' return on equity of -42.82% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A -42.82% -32.18% Salarius Pharmaceuticals N/A -324.13%-174.40% Do analysts recommend KPRX or SLRX? Kiora Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 249.65%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Salarius Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Salarius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, KPRX or SLRX? Kiora Pharmaceuticals has higher revenue and earnings than Salarius Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16.02M0.54$3.60M-$2.90-0.99Salarius PharmaceuticalsN/AN/A-$5.58M-$4.82-0.19 SummaryKiora Pharmaceuticals beats Salarius Pharmaceuticals on 10 of the 13 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.87M$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-0.198.7226.1719.90Price / SalesN/A663.86414.67113.66Price / CashN/A151.5836.1356.90Price / Book0.954.548.055.38Net Income-$5.58M$31.16M$3.15B$248.50M7 Day Performance-15.21%0.15%1.85%2.97%1 Month Performance14.80%8.81%4.81%6.02%1 Year Performance-59.15%2.55%34.86%20.39% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals1.495 of 5 stars$0.90+2.5%N/A-60.5%$1.87MN/A-0.1920Positive NewsKPRXKiora Pharmaceuticals2.5494 of 5 stars$3.13-2.2%$10.00+219.5%-35.2%$9.74M$16.02M-1.0810BTAIBioXcel Therapeutics4.297 of 5 stars$1.65+3.1%$42.60+2,481.8%-89.5%$9.69M$2.27M-0.1290News CoverageBCLIBrainstorm Cell Therapeutics4.3452 of 5 stars$1.19-2.5%$30.00+2,421.0%-79.3%$9.69MN/A-0.3540SNSESensei Biotherapeutics4.8003 of 5 stars$8.06+5.2%$90.00+1,016.6%-25.6%$9.65MN/A-0.3540Positive NewsCYCNCyclerion Therapeutics1.1399 of 5 stars$2.88-2.4%N/A+34.8%$9.47M$2M-2.4830DWTXDogwood Therapeutics2.0965 of 5 stars$4.76-2.9%$10.00+110.1%N/A$9.36MN/A-0.265Positive NewsTLPHTalphera2.7448 of 5 stars$0.44-3.4%$5.00+1,036.4%-50.8%$9.34M$650K-0.9819TRAWTraws Pharma0.2977 of 5 stars$1.55-7.2%N/AN/A$9.29M$230K-0.0517News CoverageNegative NewsKZIANovogen3.2262 of 5 stars$6.77-26.0%$57.50+749.3%-38.8%$9.22M$1.51M0.0012Positive NewsLSBLakeShore Biopharma1.0959 of 5 stars$0.95-3.1%N/AN/A$9.12M$80.82M0.00773News Coverage Related Companies and Tools Related Companies KPRX Competitors BTAI Competitors BCLI Competitors SNSE Competitors CYCN Competitors DWTX Competitors TLPH Competitors TRAW Competitors KZIA Competitors LSB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLRX Stock Alerts